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The Interdependence of 
Dermatosurgery and Dermatopathology 
Dermatologie surgery and dermatologic 
pathology cannot be practised at a 
high level unless surgeons are 
knowledgable about pathology and 
pathologists are conversant with surgery. 
Despite this reality, dermatopathology 
is not a serious component of training 
programs in dermatologic and 
plastic surgery, and dermatopathologists 
during their training are not imbued 
with principles of surgery. This colloquium 
seeks to help rectify these deficiencies 
and to educate dermatologists, 
pathologists and surgeons about matters 
of this mutual interest and concern, 
Symposia 
• General Principles 
• Melanocytic Nevi and Malignant 
Melanoma 
• Tumor Conference 
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Intravenous prostacyclin (PGI2) is a potent pulmonary vasodi­
lator in pulmonary hypertension. However, dose-dependent 
systemic vasodilation, an increase in intrapulmonary shunt 
and hypoxemia limit its clinical application. Recently, inhaled 
nitric oxide (NO) has been reported to elicit selective pulmo­
nary vasodilation, but its clinical use is restricted by its poten­
tial toxicity; furthermore, the feasibility of NO application in 
clinical practice seems difficult. Therefore, we investigated the 
effects of PGI2 aerosol on pulmonary and systemic circulation 
and compared the hemodynamic effects to those of inhaled 
NO. In 6 dogs, ventilation with a hypoxic gas mixture (F1O2 
0.09-0.11) increased pulmonary vascular resistance (PVR) by 
196% (HPV). Aerosolization of a PGI2 solution at a concentra­
tion of 430 ng/ml reduced hypoxia-induced increase of pulmo­
nary artery pressure by 48% and PVR by 52% within 6-10 min 
without systemic vasodilation. The administered dose of PGI2 
was 0.87 ± 0.26 ng/kg/min. In 2 dogs, doubling the PGI2 con­
centration (860 ng/ml) did not enhance the vasodilatory effect. 
After termination of PGI2 inhalation, HPV was restored within 
10-15 min. Inhaled NO (50 ppm) decreased the HPV-induced 
increase in PAP by 76% and in PVR by 73% within 5-10 min. 
Clinically relevant systemic vasodilation was not observed. It is 
concluded that inhalation of aerosolized PGI2 leads to selective 
pulmonary vasodilation in hypoxia-induced pulmonary hyper­
tension. Aerosolized PGI2 at a concentration of 430 ng/ml was 
less potent than NO (50 ppm). However, due to the lack of 
known toxicity and its uncomplicated mode of application, 
inhaled PGI2 may be one alternative to inhaled NO in the treat­
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Prostacyclin (PGI2), an arachidonic acid 
metabolite, is a potent pulmonary vasodilator 
[1]. It has been successfully given intrave­
nously to decrease pulmonary artery pressure 
(PAP) in primary pulmonary hypertension 
[2], in patients with ARDS [3], and in various 
experimental models of acute pulmonary hy­
pertension [4-6]. The vasodilatory effect of 
PGI2 is, however, not restricted to the pulmo­
nary circulation. When infused intravenously, 
PGI2 leads to dose-dependent systemic vaso­
dilation and hypotension. Furthermore, intra-
pulmonary shunt and venous admixture in­
crease dose-dependently; consequently, ar­
terial oxygen content decreases and the net 
effect of intravenous PGI2 on oxygen delivery 
depends on the ability to increase cardiac out­
put. For these reasons, the clinical use of 
intravenous PGI2 to treat pulmonary hyper­
tension is limited [1-3, 7]. 
Recently, inhaled gaseous nitric oxide 
(NO), considered to be identical with endo­
thelial derived relaxing factor [8], has been 
described to act as a selective pulmonary va­
sodilator in pulmonary hypertension [9, 10]. 
In awake and spontaneously breathing lambs, 
inhaled NO reduced acute pulmonary hyper­
tension induced by hypoxia or by intravenous 
infusion of the stable endoperoxide analogue 
U-46619 without being associated with sys­
temic vasodilation. Experimental studies 
have demonstrated that inhaled NO improves 
the ventilation/perfusion mismatch in hypox­
ia-induced pulmonary hypertension and is ef­
ficient in reversing pulmonary hypertension 
due to sepsis [11,12]. 
In mechanically ventilated sheep inhala­
tion of NO (20 ppm) had no effect on pulmo­
nary gas exchange but decreased blood flow to 
unventilated and poorly ventilated areas of 
the lung (ventilation/perfusion ratio <0.1) 
and consequently reduced ventilation/perfu­
sion mismatch [11]. In addition to its effects 
on pulmonary circulation and arterial oxygen­
ation inhaled NO exerts dilation of the bron­
chial smooth muscles which might improve 
pulmonary ventilation/perfusion ratio [13]. 
Inhaled NO had no effect on pulmonary he­
modynamics or gas exchange when applied 
during normoxia (F1O2 0.21) [11]. 
In experimetal models of sepsis using infu­
sion of endotoxin [14] or group Β streptococ­
cus [12] inhalation of NO diminished pulmo­
nary vasoconstriction. In the latter study in 
ventilated piglets inhalation of 150 ppm of 
NO reversed pulmonary hypertension during 
the early (<1 h) and late phase of sepsis (2 to 
6 h) whereas ventilation/perfusion mismatch 
was not counteracted in the late phase of sep­
sis [12]. More recently inhaled NO was thera­
peutically applied in man. In a restricted 
number of patients, inhaled NO proved effi­
cient in lowering PAP; however, in contrast to 
intravenous PGI2, inhaled NO caused no sys­
temic vasodilation [7, 15, 16]. 
In the most recent human studies low 
doses of inhaled nitric oxide (20 to 80 ppm) 
decreased pulmonary artery pressure in hyp­
oxia-induced pulmonary hypertension in vol­
unteers [17], in cardiac patients before and 
after cardiopulmonary bypass [18] and in 
children with pulmonary hypertension due to 
congenital heart disease [19]. 
In adults with respiratory distress syndrome 
(ARDS) inhalation of NO (5 to 36 ppm) re­
duced pulmonary artery pressure and intrapul-
monary shunting and improved arterial oxy­
genation for up to 53 days without tachyphy­
laxis and noticeable side effects. Though in the 
same study intravenous prostacyclin (4 ng/kg/ 
min) lowered pulmonary artery pressure as 
well, systemic arterial pressure fell and intra-
pulmonary shunt increased [20]. 
Finally, NO (10 ppm) inhaled for 30 min­
utes by an infant after cardiac surgery im­
proved gas exchange permanently while pul­
monary hypertension was resolved perma­
nently [21]. Furthermore, enhanced resolu-
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tion of pneumonic infiltrates was observed 
upon NO inhalation [22]. 
Despite the convincing evidence that in­
haled NO leads to selective pulmonary vaso­
dilation and hence may be useful to treat pul­
monary hypertension, it should be noted that 
NO itself is a radical with potential cytotoxic 
effects. Although severe acute lung injury and 
methemoglobinemia are observed after inha­
lation of gas mixtures containing high concen­
trations of NO, there is little evidence for pul­
monary toxicity at low concentrations (<100 
ppm) of NO inhaled for short periods of time 
in different species [10]. However, little is 
known about the toxicity of long-term breath­
ing of NO at low concentrations and the effect 
of NO on lungs with pre-existing acute or 
chronic disease. As long as the absence of 
long-term toxicity of NO has not been demon­
strated, its routine clinical application for se­
lective pulmonary vasodilation is restricted 
[10]. Furthermore, for the application of gas­
eous NO, a specially designed ventilator and 
an expensive chemiluminescence analyzer for 
continuous monitoring of the inspiratory NO 
and NO x concentrations are mandatory; 
hence it is questionable whether NO inhala­
tion will become clinical routine. 
In view of these limitations of both inhaled 
NO and intravenous PGI2, the present study 
was designed to investigate the effect of PGI2 
inhaled as an aerosol on hypoxic pulmonary 
vasoconstriction in dogs. We hypothesized 
that inhaled PGI2 may lead to selective pul­
monary vasodilation via direct relaxation of 
pulmonary vascular smooth muscle cells. Va-
sodilatory effects on both the pulmonary and 
the systemic circulation were assessed. To 
evaluate the relative potency of inhaled PGI2 
at the concentration used, its vasodilatory 
effect was compared to that of inhaled NO at 
a concentration (50 ppm) known to cause a 
nearly maximal vasodilatory effect in HPV-
induced pulmonary hypertension [10]. We 
aimed to answer the question w h e t h er inhaled 
PGI2 induces pulmonary vasodilation with­
out causing systemic hypotension. 
Methods 
Animal Preparation 
The studies were performed in 6 foxhounds of ei­
ther sex (mean body weight 27.6 ± 1.9 kg). All animals 
received care in compliance with the 'Guide for the 
Care and Use of Laboratory Animals' [ N I H Publ. No. 
85-23, revised 1985]. The study was approved by the 
institutional animal care and use committee. 
After premedication with propiomazine (1.5 mg/kg 
i.m., Combelen®, Bayer A G , Leverkusen, F R G ) , anes­
thesia was induced by intravenous injection of pento­
barbital (20 mg/kg, Nembutal®, Ceva, Bad Segeberg, 
F R G ) , piritramide (0.75 mg/kg, Dipidolor®, Janssen, 
Neuss, F R G ) and alcuronium (0.25 mg/kg, Alloferin®, 
Roche, Grenzach-Whylen, F R G ) , and maintained by 
continuous intravenous infusion of pentobarbital 
(5 m g - k g " 1 ^ - 1 ) . After termination of the surgical 
preparation an additional infusion of piritramide 
(150 μ g · k g - 1 · h - 1 ) and alcuronium (75 μ g · k g - 1 ^ h - 1 ) 
was started. Fluid losses were replaced by intravenous 
infusion of Ringer's solution (5 m l - k g - 1 - h _ 1 ) . A warm­
ing pad was used to keep core body temperature 
between 35.5 and 37 ° C . The dogs were endotracheal^ 
intubated and mechanically ventilated at a rate of 12 
cycles/min using a FiO? of 0.5 (Servo 900B, Siemens-
Elema, Solna, Sweden). Tidal volume ( V T ) was ad­
justed to maintain an arterial Pco 2 ° f 35-40 mm Hg. 
Fluid-filled catheters (PP270, Portex, Hythe, U K ) 
were positioned in the descending aorta and superior 
caval vein via the left femoral artery and the right 
external jugular vein to measure mean arterial (MAP) 
and central venous pressure ( C V P ) , respectively. A 
Swan-Ganz catheter (model 93A-431-7.5F G , Baxter 
Healthcare Corp., Santa Ana, Calif., U S A ) was in­
serted into the pulmonary artery via the right external 
jugular vein to measure mean P A P and cardiac output 
(CO) . After median sternotomy and pericardiotomy 
prewarmed, precalibrated tip manometers ( P C 370, 
Millar Instruments, Houston, Tex., U S A ) were in­
serted into the right ventricle ( R V ) via a stab incision 
at the apex of the R V and into the left ventricle ( L V ) 
via the right carotid artery. In four dogs an ultrasonic 
flow probe (Transonic Systems Inc., Ithaca, N . Y . , 
U S A ) was placed around the pulmonary artery. At the 
end of the surgical preparation, the pericardium was 
closed with running suture to avoid constraint to the 
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myocardium. Thereafter, a chest tube was inserted, the 
thorax was closed air-tight, and the lungs were com-
pletely reinflated. Subsequently, the dogs were turned 
to the left lateral decubitus position. 
Administration of NO 
N O was obtained in 50-liter cylinders as a precise 
mixture of 200 ppm N O in nitrogen (Linde A G , U n -
terschleissheim, F R G ) . During inspiration the N O / N 2 
mixture was introduced into the inspiratory gas using a 
T-tube connected to the endotracheal tube. A magnetic 
valve (Servo Nebulizer 945, Siemens, Erlangen, F R G ) 
triggered by the electronic regulation system of the 
ventilator was used for insufflation of N O exclusively 
during inspiration. The inspiratory N O flow was var-
ied using a precise pressure reduction valve (SP 
750.0183.M, Kuhnke, Malente, F R G ) and the N O 
pressure was monitored with an electronic manometer 
(Type 352-P, Debro G m b H , Meerbusch, F R G ) . The 
correct inspiratory N O concentration was produced by 
varying the N O admixture to the inspired gas mixture 
at constant tidal volumes (Ty). The F1O2 was main-
tained constant during administration of the N O / N 2 
mixture by increasing the inspiratory oxygen concen-
tration proximal to the N O insufflation port. The 
inspired oxygen concentration (F1O2) was continuous-
ly monitored distal to the N O insufflation port (Oxy-
dig, Dräger A G , Lübeck, F R G ) . Expired gas was scav-
enged and discarded. Prior to the experiments the 
complete application system (ventilator, pressure re-
duction valve, electronic manometer) had been cali-
brated to achieve the desired inspiratory N O concen-
tration at different T y and oxygen concentrations us-
ing a chemoluminescence N O / N O x analyzer (Beck-
man, Model 951 A, Beckman Instruments, Munich, 
F R G ) . The inspiratory N O concentration at a given 
system setting varied no more than 3% during re-
peated calibration measurements. 
To avoid oxidation of N O to N O 2 , the critical con-
tact time of N O and O2 during inspiration [10] has 
been kept short by using a short inspiration time 
(1.65 s) and by introducing N O into the inspiratory gas 
mixture very close to the endotracheal tube (19 cm). 
The concentrations of N O 2 measured at the endotra-
cheal tube during calibration were below 1 ppm. 
Administration of PGI2 Aerosol 
For inhalation of P G I 2 as aerosol, a jet nebulizer 
(Servo Nebulizer 945, Siemens, F R G ) was connected 
to a Siemens 900B ventilator. The nebulizer chamber 
(Intersurgical Ltd, Twickenham, U K ) was located 
16 cm from the endotracheal tube. The jet flow sup-
plied to the nebulizer chamber during inspiration was 
kept constant in all experiments at a flow rate of 
14 liters/min. This high flow rate was chosen because 
the fraction of particles with a diameter of < 2 μ ι η , 
which are likely to settle in the alveolar region of the 
lung, increases with flow rate. T y and total inspiratory 
flow rate were maintained constant during aerosoliza-
tion by decreasing the inspiratory flow from the venti­
lator. Total T v was monitored ( C O 2 analyzer 930, 
Siemens-Elema). 
P G L was supplied as the sodium salt of epoproste-
nol (Flolan®, Wellcome, London, U K ) dissolved in gly­
cine buffer of p H 10.5 at a concentration of 10 μg/ml; 
the solution was prepared on the day of the experiment 
and stored on ice until use. Prior to inhalation, P G L 
was further diluted with normal saline to a concentra­
tion of 430 ng/ml and a total volume of 10 ml of this 
solution was filled into the nebulizer chamber. The 
dosage of P G L was based on pilot experiments in 
which this concentration has proven to be effective in 
lowering P A P . T o assess the actual amount of P G L 
nebulized, the total volume of the P G I 2 solution in the 
nebulizer chamber was measured prior to and imme­
diately after inhalation (volume nebulized χ concen­
tration/duration of inhalation). 
6-keto-Prostaglandin-F l c t (6-keto-PGFi a ) , the sta­
ble metabolite of P G L , was measured by radioimmu­
noassay (antibody: Pasteur Diagnostic, Marne-la-
Coquette, France; 3 H-PG's : Amersham Buchler, 
Braunschweig, F R G ) in unextracted arterial plasma 
before and after P G L inhalation in 3 dogs. 
T o exclude that the vasodilatory effect of P G L 
aerosol was mediated by uptake of P G I 2 into the blood, 
the effects of P G L infused at a rate of 1 and 2 ng/ 
kg/min were compared to those of inhaled P G L in 
2 dogs. 
Measurements 
Hemodynamics. All measurements were per­
formed with the dogs in left lateral position. M A P , 
P A P , and C V P were recorded (Astromed M T 9500, 
Astro-Med, Inc., West Warwick, R . I . , USA) using Sta-
tham P23Db transducers (Gould-Statham, Oxnard, 
Calif., U S A ) referred to the right atrium. E C G and 
ventricular pressures ( L V P , R V P ) were sampled every 
4 min, digitized in real-time (A/D converter C1000, 
Cosima Corp., Salem, Oreg., USA) and stored for eval­
uation using a P C / A T 386 computer system. Data 
were analyzed with interactive software ('Meduse', 
Η. Zeintl, Neckargemünd, F R G ) . All parameters were 
evaluated at end-expiration using the average of three 
consecutive heart beats. 
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In the R V and L V , maximal ( R V P m a x , L V P m a x ) and 
end-diastolic pressures ( R V E D P , L V E D P ) were as­
sessed. C O was obtained from triplicate thermodilu-
tion measurements at end-expiration ( R E F - 1 ™ , Ejec­
tion Fraction/Cardiac Output Computer, Baxter 
Healthcare, Santa Ana, Calif., USA) . 
T h e following parameters were calculated: 
C I = 1 0 - C O B W - 0 7 5 
(according to Holt et al. [23]) 
P V R = ( P A P m e a - L V E D P ) · 79.9 · C O " 1 
S V R = ( M A P m e a - R V E D P ) . 79 .9 -CO" 1 
where C I = cardiac index, C O = cardiac output, B W = 
body weight, P V R = pulmonary vascular resistance, 
L V E D P = L V end-diastolic pressure, S V R = systemic 
vascular resistance, R V E D P = right ventricular end-
diastolic pressure, H R = heart rate. 
Lung Function. Po2> Pco 2 a n d p H ( A B L 300, R a ­
diometer, Copenhagen, Denmark), as well as arterial 
(Sa02) and mixed venous oxygen saturation ( S y O i ) 
and arterial methemoglobin fraction (CO-Oximeter 
282, Instrumentation Laboratory Inc., Lexington, 
Mass., U S A ) were analyzed. End-tidal CO2 concentra­
tion and T v were monitored using a CO2 analyzer (CO2 
analyzer 930, Siemens-Elema), airway pressures (P p e ak> 
Ppiat) and total thoracic compliance ( C t o t ) were assessed 
(Lung Mechanics Calculator 940, Siemens-Elema). 
Experimental Protocol 
After termination of surgery the dogs were isovolu-
mically hemodiluted with 6% dextran 60 (Makrodex®, 
6%, Schiwa, Glandorf, F R G ) to a hematocrit of 27 -
30% in order to achieve identical values of hematocrit 
and hemoglobin in all animals. The withdrawn blood 
was used to replace blood samples taken for laboratory 
analysis. Hematocrit and hemoglobin did not change 
significantly during the experiment. 
Control measurements were performed 30 min af­
ter termination of surgery under stable hemodynamic 
conditions (control). Thereafter, hypoxia was induced 
by decreasing the F1O2 to 0.09-0.11 to achieve a Pa02 
of near 40 mm Hg. The inspired FiO? was monitored 
and PaC02 was maintained constant by adjusting V T . 
Following a period of stable hemodynamics, baseline 
recordings were obtained during hypoxia ( H P V ) . Sub­
sequently, either N O at a concentration of 50 ppm or 
P G L at a concentration of 430 ng/ml were adminis­
tered in random order. Measurements were obtained 
after 10 min of N O or P G L application, respectively 
(NO, P G I ) . Subsequently, the administration of either 
N O or P G L was terminated and a further measure­
ment under hypoxic conditions was performed (post-
N O , post-PGI) 10-15 min thereafter. 
Statistical A nalysis 
Data are reported as mean ± S D . Statistical analy­
sis was performed using a repeated measures analysis 
of variance ( r A N O V A ) . If the f value was significant 
(p < 0.05), the following time points were compared by 
paired t test: control vs. H P V , H P V vs. N O , H P V vs. 
P G L as well as the difference between H P V and N O 
versus the difference between H P V and P G L . Bonfer-
roni correction was applied as appropriate. Differences 
were considered significant for ρ < 0.05. 
Results 
Hemodynamics 
The effects of NO and PGI2 on hypoxia-
induced changes in pulmonary and systemic 
hemodynamics are summarized in figure 1. 
Aerosolization of the solvent (glycine buffer, 
pH 10.3) and normal saline did not exert 
effects on systemic or pulmonary hemody­
namics. 
Hypoxia. Ventilation with a hypoxic gas 
mixture (F1O2 0.09-0.11) produced a signifi­
cant increase in PAP (+57%, ρ < 0.001), PVR 
(+196%, ρ < 0.001), heart rate (control 99 ± 
11, HPV 135 ± 30, ρ < 0.01) and CI (control 
2.3 ± 0.3, HPV 3.0 ± 0.5, ρ < 0.05) as well as 
a reduction in SVR (-26%, ρ < 0.05) in all 
dogs (fig. 1). The degree of hypoxic pulmo­
nary vasoconstriction as assessed by PVR re­
mained constant during basic HPV, post-NO 
and post-PGI. Right and left ventricular pre­
load (RVEDP, LVEDP) remained constant. 
Nitric Oxide. When NO was added to the 
hypoxic gas mixture, PAP was significantly 
reduced in all dogs (-28%, ρ < 0.001 vs. HPV) 
but did not reach baseline levels (F1O2 0.5). 
NO attenuated the HPV-induced increase in 
PAP and PVR by 76 and 73%, respectively 
(fig. 1). A minor reduction in MAP (-5%, ρ < 
0.05 vs. HPV) was observed, however, there 
was no change in calculated SVR (fig. 1). The 
maximal pulmonary vasodilating effect of 
NO occurred within 7 ± 1.3 min (fig, 2). Af­
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Fig. 1. Effects of inhalation of NO (n = 6) and P G I 2 (n = 6) during hypoxia on P A P , M A P , 
P V R and S V R . Inhalation of N O and P G I 2 decreased P A P and P V R reversibly while M A P 
and S V R remained unchanged. Data are given as mean ± S D . C O N T = Control before hyp­
oxia. * ρ < 0.05; ** ρ < 0.01; *** ρ < 0.001 versus preceding measurement. 
namic variables returned to pre-NO values. 
During inhalation of NO, HR, CI, LVEDP 
and RVEDP remained unchanged. 
Mean methemoglobin levels increased 
from 0.8 ± 0.2 to 1.2 ± 0.3% after NO inha­
lation (p < 0.05) and returned to baseline val­
ues after termination of NO application. 
Prostacyclin. Inhalation of PGI2 aerosol 
during HPV decreased PAP and PVR by 17 
and 32%, respectively (fig. 1). The hypoxia-
induced increase in PAP was reduced by 48% 
and the increase in PVR by 52%. No signifi­
cant changes occurred in MAP (-2 ± 5 mm 
Hg),SVR(+83 ± 124dyn.cm.s-5)(fig. 1),CI 
(-0.25 ± 0.27 liter/min) and RVEDP. During 
PGI2 inhalation, HR was slightly reduced 
(HPV 139 ± 27, PGI 127 ± 27, ρ < 0.05). 
The maximal pulmonary vasodilating effect 
of PGI2 was achieved within 8 ± 1 min 
(fig. 2). The decrease in PAP induced by PGI2 
was smaller compared to the effect of NO in 
all dogs (p < 0.02). After termination of PGI 2 
administration, hypoxic pulmonary vasocon­
striction was restored within 10-15 min. 
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Fig. 2. Sequential changes of P A P during inhalation of N O (n = 6) and P G L (n = 5). N O 
and P G b led to an immediate decrease of P A P that reached its maximum within 10 min with 
both substances; the magnitude of PAP and P V R change was greater during N O than during 
P G L inhalation (p < 0.05). Data are given as mean ± S D . 
Table 1. Blood gas and respiratory parameters at control, at baseline H P V and during N O and P G I 2 inhala­
tion 
Variables Control HPV HPV + NO Post-NO HPV HPV + P G I 2 Post-PGI2 
Pa0 2 . mm Hg 186±65 4 1 ± 9 . 6 a 42.4±9.2 41.1 ±9.6 40.8±9.7 45 .1±13 .1 c 39.6±5.2 
Ρ ν Ό 2 . mm Hg 46.1 ±3 .0 2 7 . 6 ± 5 . 3 b 28.4±5.0 27.8±5.2 27.1 ±5.2 29 .0±5.4 C 26.6±3.5 
P a C Ö 2 , mm Hg 38.9 ±2 .0 37.6±2.8 37.2±2.1 35.3±2.9 36.3±2.9 33.5±4.5 36.5±6.6 
pH art 7.36±0.06 7.36±0.03 7.36±0.03 7.37 ±0.04 7.38±0.04 7.39±0.05 7.36±0.05 
COM, ml/cm H 2 0 59.5 ±18 .4 52.8±14.3 53.5±15.0 50.8±13.5 50.3±14.8 51.0± 12.2 50.7± 14.1 
AWPpi a t, mbar 12.0±2.2 11.7±2.7 11.0±1.7 12.2±2.6 12.5 + 3.0 11.7±1.8 11.8±3. l 
Data are given as mean ± SD. Pa0 2 = Arterial 0 2 tension; Pv0 2 = mixed venous 0 2 tension; PaC0 2 = arterial C 0 2 tension; 
pH art = arterial pH; COM = total compliance of lung and thoracic wall; AWP p i a l = plateau airway pressure at end inspiration. 
a ρ < 0.05; b ρ < 0.01 HPV vs. control; c ρ < 0.05 PGI 2 vs. HPV. 
The mean effective dose of PGI2 adminis­
tered to the lungs was 0.87 ± 0.26 ng/kg/min. 
Intravenous infusion of PGI2 at comparable 
infusion rates (1 and 2 ng/kg/min) in 2 dogs 
had neither effects on pulmonary nor sys­
temic hemodynamics (data not shown). 
Plasma concentrations of 6-keto-PGFia 
measured in 3 dogs before, during and after 
PGI2 inhalation remained unchanged (HPV 
94 ± 50 pg/ml, PGI 112 ± 20 pg/ml, post-
PGI 103 ± 9 pg/ml). 
Lung Function 
Blood gas parameters and lung mechanics 
are summarized in table 1. Ventilation with 
the hypoxic gas mixture (F1O2 0.09-0.11) re-
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suited in a decrease of mean arterial Po2 from 
186 ± 65 mm Hg and mean PvC>2 from 46.1 
± 3.0 to 41 ± 9.6 mmHg and 27.6 ± 5.3 mm 
Hg, respectively. Arterial and mixed venous 
Po2 remained constant during ventilation 
with the hypoxic gas mixture. There was no 
significant change in arterial Pco2 throughout 
the experiments. Mean arterial pH was main-
tained between 7.36 and 7.39. PaC>2 and PvC>2 
increased slightly and reversibly only during 
PGI2 inhalation. There was no change in air-
way pressures (Pp eak, Ppiat)- Total thoracic 
compliance slightly decreased after induction 
of hypoxia, but remained constant during NO 
and PGI2 administration. 
Discussion 
The main finding of this study was that 
inhaled PGI2 selectively attenuated hypoxia-
induced pulmonary hypertension without 
causing systemic vasodilation. Both PGI2 
aerosol and NO gas reduced hypoxia-induced 
increase in PVR within minutes without af-
fecting systemic vascular resistance or CI; the 
effects on the pulmonary vessels were revers-
ible upon termination of either drug within 
10-15 min. 
PGI2 is the main metabolite of arachidonic 
acid produced by endothelial cells in different 
species. It is a potent dilator of both arteries 
and veins [24]. The vasodilatory effect is en-
dothelium independent and is mediated by 
stimulation of specific receptors on mem-
branes of vascular smooth muscle cells [25]. 
Intracellular^ PGI2 acts by increasing the con-
centration of cyclic adenosine monophos-
phate (cAMP) [25]. PGI2 has a rapid onset of 
action and a short half-life (2-3 min) when 
infused intravenously. Due to the lack of a 
carrier mechanism to transfer PGI2 across the 
cell membrane, it is, unlike most other prosta-
glandins, not metabolized by the lung and 
retains its pulmonary vasodilatory properties 
[26]. Therefore, and because of its lack of 
known toxicity, PGI2 aerosol was chosen for 
inhalation. 
Since the first description of the dilating 
effects on pulmonary and systemic vessels of 
intravenous PGI2 in dogs [1], it has been suc-
cessfully applied as pulmonary vasodilator in 
animal models of acute pulmonary hyperten-
sion [4, 5, 27, 28] and in patients with pulmo-
nary hypertension of various etiologies [2, 
29]. At doses effective in reducing PVR, intra-
venous PGI2 did, however, induce systemic 
vasodilation and an increase in cardiac out-
put. In addition, intravenous PGI2 was shown 
to attenuate HPV and to increase venous 
admixture; consequently, arterial oxygen con-
tent decreases and the net effect of intrave-
nous PGI2 on oxygen delivery depends on the 
ability to increase cardiac output [4, 30]. 
In this study, the inhalation of PGI2 aero-
sol reduced the hypoxia-induced increase in 
PAP and PVR without eliciting systemic va-
sodilation or changes of CI. The finding that 
inhaled PGI2 did not completely reverse HPV 
is in agreement with the results of previous 
studies, in which PGI2 given intravenously 
also failed to completely abolish the hypoxia-
induced increase in PVR [5, 28]. 
In contrast to intravenous PGI2, PGI2 
aerosol did not increase cardiac output. 
Therefore, the calculated PVR, which was 
used in this study to assess pulmonary vascu-
lar tone and that is influenced by changes of 
cardiac output, may truly reflect PVR 
changes. 
In contrast to the decrease in Pa02 occur-
ring during intravenous infusion of PGI2, the 
inhalation of PGI2 produced a small and 
reversible increase in Pa02 and Pv02. This 
finding cannot be easily explained from our 
data. One may speculate that PGI2 inhalation 
led to a reduction in V a/Q mismatches as it 
has been described during NO inhalation in 
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patients with ARDS [7]. However, in this 
study, NO did not affect either arterial or 
mixed venous oxygenation during inhalation. 
The effect of inhaled PGI2 on pulmonary ven­
tilation/perfusion ratio has to be assessed in 
further studies using more appropriate tech­
niques (e.g. multiple inert gas elimination 
technique). 
The mean dose of PGI2 aerosolized was 
0.87 ± 0.26 mg/kg/min. Doubling the con­
centration of the PGI2 solution (860 ng/ml) at 
constant inspiratory flow, and hence presum­
ably doubling the dose administered, did not 
enhance the effect on pulmonary or systemic 
hemodynamics. So far, we have not yet estab­
lished the minimal effective dosage of inhaled 
PGI2, therefore we cannot exclude that a high­
er concentration of the PGI2 solution might 
have a more pronounced effect. Furthermore, 
it cannot be excluded that inhalation of PGI2 
at higher concentrations might affect systemic 
hemodynamics. In patients with bronchial 
asthma, systemic vasodilation has been re­
ported following the short-time inhalation 
(maximal time of inhalation 3 min) of consid­
erably higher doses of PGI? (200-400 μg) 
[31]. 
It should be noted that the dose of PGI2 
administered was assessed by measuring the 
volume of the PGI2 solution in the nebulizer 
chamber before and after inhalation; this dose 
may, however, not reflect the actual amount 
of PGI2 inhaled as it does not account for 
losses in the nebulizer, the ventilator tubing, 
the endotracheal tube and the extrapulmona­
ry airways. Using radiolabeled aerosol, it has 
been demonstrated that during mechanical 
ventilation only a small fraction of a given 
dose of aerosol (0.37-3.68%) is actually de­
posited in the lung [32]. Therefore, the effec­
tive dose of inhaled PGI2 may be considerably 
lower than calculated. Furthermore, it must 
be emphasized that the actual output of nebu­
lizers is influenced by the type of nebulizer 
used, by the volume initially placed in the 
nebulizer and by the ventilator setting [33]. 
Still, the dose of PGI2 aerosol effective in 
reducing HPV in this study is considerably 
lower than the dose of intravenously given 
PGI2 necessary to lower PAP in different 
models of experimental pulmonary hyperten­
sion (249 ± 69 ng/kg/min [4], 79 ± 5 μg/kg/ 
min [5]) or in patients with pulmonary hyper­
tension of various origin (7.1-35.0 ng/kg/ 
min [3,29]. In 2 dogs the intravenous infusion 
of PGI2 at a rate of 1 and 2 ng/kg/min - com­
parably to the inhaled dose - neither caused 
pulmonary nor systemic vasodilation and had 
no effect on CO (data not shown). 
Our findings indicate that aerosolized 
PGI2 at the concentration used in this study 
acts predominantly on smooth muscle cells in 
the lung vessels and does not reach the sys­
temic circulation in efficient amounts. This 
view is supported by the fact that the arterial 
concentration of 6-keto-PGFia, the main me­
tabolite of PGI2, did not increase during inha­
lation of prostacyclin. From our data, how­
ever, we cannot decide whether the selective 
pulmonary dilation was due to the low con­
centration of inhaled PGI2 or whether it is 
exclusively the route of administration that 
prevents systemic effects of the drug. 
A reduction in PAP and PVR has pre­
viously been reported upon inhalation of 
aerosolized arachidonic acid in dogs [34]. The 
pulmonary changes were, however, accompa­
nied by systemic vasodilation and by bron-
chocon strict ion indicating that prostaglandin 
precursors were absorbed and metabolized 
into different prostanoids in lung tissue. In 
contrast, prostacyclin administered as aerosol 
is neither transformed into an active form nor 
metabolized by the lung [26]. Although we did 
not measure dynamic compliance and airway 
resistance, we observed no change in total 
static compliance and in plateau airway pres­
sure during PGI2 inhalation. Hence, PGI2 
337 
aerosolized at low concentrations appears to 
act as pulmonary vasodilator without causing 
side effects (e.g. bronchoconstriction) attrib-
utable to other arachidonic acid metabolites 
or to systemic absorption. 
In this study, we compared PGI2 aerosol to 
NO in order to assess the maximal dilation of 
pulmonary vessels that can be pharmacologi-
cally achieved during HPV without systemic 
side effects. We chose an inspiratory concen-
tration of 50 ppm NO, because it has been 
demonstrated that a further increase of the 
inspiratory NO concentration produces vir-
tually no additional vasodilatory effect [10]. 
In this study, the inhalation of NO at a con-
centration of 50 ppm produced a reduction of 
hypoxia-induced increases in PAP by 76% 
and in PVR by 73% accompanied by a slight 
decrease in arterial pressure (fig. 1) and no 
change in cardiac output. A complete reversal 
of hypoxic pulmonary vasoconstriction, as 
demonstrated in spontaneously breathing 
sheep at a NO concentration of 40 ppm [10], 
was not achieved in ventilated dogs in this 
study. The failure of NO to reverse HPV com-
pletely may be partially explained by species 
differences or by positive pressure ventilation 
producing a more heterogeneous distribution 
of pulmonary ventilation and blood flow. The 
slight systemic vasodilation observed was not 
reported in other studies [9, 10]. 
At the concentrations used, the magnitude 
of pulmonary vasodilation was more pro-
nounced during NO than during PGI? inhala-
tion. However, PGI2 infused intravenously 
did not fully reverse HPV [5, 28]. Thus, 
inhaled NO may be the more potent pulmo-
nary vasodilator when compared to prostacy-
clin at both routes of administration. 
It must be noted that NO is a radical (*N = 
O) with the potential for cytotoxicity. Super-
oxide (O2) and NO, which both are generated 
by endothelial cells, macrophages and neu-
trophils, combine to form peroxynitrite an-
ion (ONOO -). Peroxynitrite decomposition 
products are nitrogen dioxide and hydroxyl 
radical which exert cytotoxic effects by initiat-
ing lipid peroxidation of cell membranes [35]. 
In the presence of molecular oxygen, NO 
reacts in a concentration- and Fi02-depen-
dent manner to form nitrogen dioxide (NO2), 
which is subsequently transformed to nitric 
and nitrous acid. Severe damage to the lung 
and airways may result. NO binds avidly to 
hemoglobin to form nitrosylhemoglobin (Hb-
NO) which is subsequently oxidized to methe-
moglobin (Met-Hb). Reduction of Met-Hb oc-
curs, however, much slower than Met-Hb for-
mation from Hb-NO and the rate of Met-Hb 
reduction is decreased by increasing NO con-
centrations [36]. Although Met-Hb plasma 
concentrations at doses of NO inhaled for pul-
monary vasodilation remain low (<l-2%), 
methemoglobinemia following inadvertent 
overdosage of NO may lead to critical reduc-
tion of oxygen transport. Oxidative cross-link-
ing of membrane proteins of erythrocytes ex-
posed to NO may impair their rheological 
properties [36]. Although there is little evi-
dence for severe toxicity at low concentra-
tions (<100 ppm) of NO inhaled for short 
time periods in different species, little is 
known about the toxicity of long-term breath-
ing of NO at low concentrations and the effect 
of NO on lungs with pre-existing acute or 
chronic disease [10]. 
The feasibility of NO inhalation in clinical 
routine seems cumbersome: due to its poten-
tial toxicity, the application of gaseous NO 
requires specially designed respirators which 
permit exact adjustment and long-term con-
stancy of the inspired NO concentration. Ex-
pensive chemiluminescence analyzers for 
continuous monitoring of the inspired NO 
concentration and for detection of NO oxida-
tion products (NO2) are mandatory and final-
ly, NO gas has not been approved for medical 
purposes so far. 
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Thus, the clinical application of inhaled 
NO as a selective pulmonary vasodilator ap­
pears limited by the lack of data on long-term 
toxicity and effects on preinjured lungs, but 
also due to the necessity of complicated and 
expensive techniques to safely allow and con­
trol NO administration. 
In contrast to the potential toxicity of NO, 
no severe toxic side effects of PGb have been 
reported. Furthermore, PGI2 can be adminis­
tered as aerosol using a standard jet nebulizer 
and no sophisticated system to monitor the 
inspired PGI2 concentration is required. In 
further studies the dose-response relationship 
for inhaled PGI2 has to be established, the 
pulmonary vasodilatory effects have to be as­
sessed in different models of pulmonary hy­
pertension and the effects of long-term inhala­
tion have to be investigated. Finally, due to 
the different mechanisms of action, the com­
bination of inhaled NO and aerosolized PGI2 
may have additive pulmonary vasodilatory 
effects. Upon clarification of these open ques­
tions, PGI2 aerosol may become an attractive 
alternative to the inhalation of NO in the 
treatment of acute pulmonary hypertension. 
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